No Photo Available

Last Update


This profile was last updated on .

Is this you? Claim your profile.

Wrong David Buswell?

Mr. David Buswell

Chief Executive Officer


Direct Phone: (917) ***-****       

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.


Background Information

Employment History

Chief Executive Officer

Immune Response BioPharma Inc

Not Applicable

none not applicable

Chief Executive Officer and Chief Financial Officer and Chief Operating Officer

The Immune Response Corporation


Bachelor’s degree

Business & Commerce

University of Mary Washington

Masters Degree

Master’s degree MA

Management & Leadership

Liberty University

Web References (15 Total References)

Immune Response BioPharma Files Amended FDA BLA for Remune - [cached]

While I won't guarantee Remune is approved the outlook for the vaccine is positive & the data warrants approval with a large safety profile and strong immune responses," IRBP CEO Mr. Buswell commented.

David Buswell 917-275-7931

We are actively seeking a funding ... [cached]

We are actively seeking a funding partner to drive this unique and wonderful treatment to the finish line and FDA approvel" IRBP CEO Mr. David Buswell

GSK has no approved MS drug ... [cached]

GSK has no approved MS drug and probably will never have one they are busy wasting their shareholders money on HGSI and a Lupus drug with poor sales, we don't need them or to give away our blockbuster drug for MS to them which we believe will become treatment of choice" IRBP CEO Mr. Buswell

"IRBP values NeuroVax north of a billion dollar of annual sales once approved. We will find a solid partner or raise capital on our own, we don't need GSK which has zer0 experience in multiple sclerosis or auto-immune diseases. GSK is a joke and seems very ignorant on how multiple sclerosis drugs work and how to develop one, we gave them a chance to develop NeuroVax but their management appears to be very poor. We have decided to terminate any collaboration or development with GSK. GSK is a loser in the MS market and will continue to be a loser" IRBP CEO Mr. Buswell
see also comment below :
38. David Buswell on May 30, 2012 1:05 AM writes...

"This recent issuance of U.S. 8,053,197 ... [cached]

"This recent issuance of U.S. 8,053,197 is a key patent in that it extends key IP coverage including FOXP3+ Expression Technology related to the delivery and composition of NeuroVax with TCR peptide vaccines including the addition of estrogen to boost the vaccine potential in women suffering from MS." said Mr. David Buswell, IRBP Chief Executive Officer.

David Buswell Immune Response BioPharma, Inc. CEO 244 5th avenue suite 1727

Executive Team [cached]

Chief Operating Officer & Chief Financial Officer & CEO: Mr. David Buswell

Mr. David Buswell is founder of Immune Response BioPharma, and is Chief Operating Officer, CFO, President & acting CEO and is Chairman of the Board of Directors. Mr. Buswell holds a Bachelor’s degree in Business & Commerce from the University of Mary Washington, and a Master’s degree MA in Management & Leadership from Liberty University.

Similar Profiles

Other People with this Name

Other people with the name Buswell

Cynthia Buswell
New York State Department

Natasha Buswell
Formby Surveys Ltd

Justin Buswell
Alert Logic Inc

Wendy Buswell
The King's School

Jonathan Buswell

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory